Skip to main content

Pcas: Net Sales as of Septembre 30, 2020

Written by Customer Service on . Posted in Public Companies.


Ecully; November 5, 2020NET SALES AS OF SEPTEMBER 30, 2020PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its net sales as at September 30, 2020.   Pharmaceutical Synthesis The Pharmaceutical Synthesis business in Health generated €96.8 million, up 8.6% compared to 2019 (+8.5% at a constant exchange rate). This growth can mainly be attributed to two effects: (i) a greater operational performance at one of our sites in the Greater Paris region and (ii) a fast mobilization of the PCAS Pharmaceutical Synthesis division in response to the health crisis caused by Covid-19, especially by producing a hand sanitizer solution marketed under the Naaha brand.Fine Specialty ChemicalsNet sales of fine specialty chemicals amounted to €44.5 million, which was down 21.3% compared to 2019 (-21.0% at a constant exchange rate). The Electronics business is well resisting against the crisis, however the demand in the Lubricants and Fine Chemicals activities has fallen significantly. The Lubricants business in particular has been severely affected by the health crisis.OutlookAs mentioned in our previous press releases since late March 2020, the global health crisis relating to the coronavirus is changing by the day, and there are still a lot of uncertainties regarding its duration, its extent and its effects on companies’ production lines and consumption in general.To date, the PCAS Group has not seen any major impacts on its business activities and earnings except for the significant fall in demand for Lubricants and the delay in commissioning the new production unit in Villeneuve-la-Garenne, which was achieved mid-October 2020. The delay in commissioning the production unit will have the effect of carrying forward approximately €5 million of net sales to 2021. In any case, it is still hard to anticipate the potential impacts in the medium term. This crisis calls for cautious measures. Due to the exceptional circumstances, the Group has suspended its financial targets and its strategic business objectives until the situation becomes clearer.NEXT FINANCIAL DISCLOSURE:Net sales at December 31, 2020 on January 28, 2021ABOUT PCASPCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 10% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €200.9 million in 2019 and employs close to 1 100 people in six countries.To find out more about PCAS: www.pcas.comAttachmentPCAS – Communiqué de presse – Chiffre d’affaires au 30 septembre 2020_eng_DEF

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.